Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 3/20 | 0.63 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11527826 | 0.98 | GABBR2 (0.61) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL15614165 | 0.94 | GABBR2 (0.58) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL6002264 | 0.94 | GABBR2 (0.58) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL1979348 | 0.90 | KMT2A (0.58) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL28280929 | 0.86 | GABBR2 (0.53) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL5709394 | 0.86 | KEAP1 (0.52) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL18055503 | 0.86 | FNTA (0.59) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL22089315 | 0.86 | GABBR2 (0.50) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL391659 | 0.84 | GABBR2 (0.79) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL10951769 | 0.84 | GABBR2 (0.52) | GABBR2GABBR1CYP2C9LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7550489-B2 | Substituted pyridyoxy amides | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1318983-B1 | SUBSTITUTED IMIDAZOLES AS HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| EP-1496838-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-6518287-B2 | Such as 2-((1-chlorophenyl-)pyridyl-)ethylamidoethyl-imidazole for treatment ofallergies, inflammatory and central nervous system-related diseases | SCHERING CORPORATION | 2003-02-11 | — | — | US | disclosed |
| WO-2002024658-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-03-28 | — | — | WO | disclosed |
| US-6350892-B1 | ENZYME INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-26 | — | — | US | disclosed |
| EP-1140791-A2 | SELECTIVE CPLA 2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140791-A4 | SELECTIVE CPLA 2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6255496-B1 | CYTOSOLIC PHOSPHATIDE 2-ACYLHYDROLASE ENZYME INHIBITORS; CONTROLLING INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-03 | — | — | US | disclosed |
| WO-1999015129-A2 | SELECTIVE cPLA2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-04-01 | — | — | WO | disclosed |
| US-4603145-A | Antiatherosclerotic diphenyl alkanamides | AMERICAN CYANAMID COMPANY (US) | 1986-07-29 | — | — | US | disclosed |
| US-4536346-A | TREATMENT OF ATHEROSCLEROSIS | AMERICAN CYANAMID COMPANY (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0124791-A1 | Aralkanamidophenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171692-A1 | Substituted amides | CNR1, CNR2, FAAH | GABBR2 194/4885GABBR1 162/4885CYP2C9 1269/4885 |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | CCKAR, CCKBR, TAS1R2 | GABBR2 1845/4885GABBR1 2805/4885CYP2C9 2955/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | GABBR2 194/4885GABBR1 162/4885CYP2C9 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.